Koehl, NiklasKuentz, Martin2021-05-102021-05-102020-06-100724-87411573-904X10.1007/s11095-020-02841-9https://irf.fhnw.ch/handle/11654/32421Conclusion: Chase dosed LBF enhanced the in vivo bioavailability of nilotinib. Long chain lipids showed superior performance compared to medium chain lipids. Chase dosing appeared to prolong the absorption phase of the drug. Therefore, chase dosing of LBF is favourable compared to lipid suspensions for 'brick dust' molecules such as nilotinib. Graphical Abstract The potential of bio-enabling lipid vehicles, administered via chase dosing and lipid suspensions, has been evaluated as an approach to enhance oral bioavailability of nilotinib.enbrick dust moleculechase dosinglipid based formulationpoorly water-soluble drugs01A - Beitrag in wissenschaftlicher Zeitschrift124